The FDA approved Pluvicto with androgen receptor inhibitors for earlier-stage PSMA-positive metastatic hormone-sensitive prostate cancer, expanding patient eligibility.

The FDA approved Pluvicto with androgen receptor inhibitors for earlier-stage PSMA-positive metastatic hormone-sensitive prostate cancer, expanding patient eligibility.

The FDA approved Pluvicto with androgen receptor inhibitors for earlier-stage PSMA-positive metastatic hormone-sensitive prostate cancer, expanding patient eligibility.